GZBL(SZ:002424) Xin Lang Cai Jing·2025-11-13 08:34Core Insights - Guizhou BaiLing conducted an institutional research meeting on November 12, 2025, attracting 15 institutions and several individual investors to discuss core product development, supply chain management, market expansion, and financial status [1] Product Development Progress - The focus of the research was on the development of two core products: Tang Ning Tong Luo and Huang Lian Jie Du Wan. Tang Ning Tong Luo has received approval for its first indication, diabetic retinopathy, and has entered phase III clinical trials with 360 patients being enrolled. The company plans to submit a market application after completing the trials. Additionally, the drug has received a clinical trial approval for type 2 diabetes, with plans to advance to phase II trials [2] - Huang Lian Jie Du Wan, as China's first "syndrome" type traditional Chinese medicine new drug, has completed phase II and III clinical trials over six years. The phase III trials evaluated its effectiveness, safety, and mechanism for treating traditional Chinese medicine's "excess heat and toxin syndrome." The project is now preparing for pre-market communication [2] Supply Chain and Market Strategy - Guizhou BaiLing has planted nearly 250,000 acres of medicinal herbs to ensure supply chain stability, implementing large-scale cultivation of over 20 varieties, including landmark herbs like Jixiang Grass and Tiger Ear Grass. The company has established a standardized control system to address the shortage of wild medicinal resources and ensure quality [3] - The market expansion strategy focuses on a "first in-hospital, then out-of-hospital" approach, targeting grassroots medical institutions, pharmacy chains, and private clinics. The "5+5" promotion plan aims to cover five quality clinics and five individual pharmacies, supported by professional talent recruitment and team motivation [3] Financial Status - The company reported a stable cash flow and a decrease in total bank loans, having optimized sales models and adjusted payment management processes to enhance cash flow [4] - Institutional investors expressed interest in Guizhou BaiLing's strategies in core product development, supply chain management, and market expansion, with the company committed to advancing its projects and optimizing its strategies for long-term growth [4]